PE20140391A1 - 1h-pirazol-5-olato sodico sustituido - Google Patents
1h-pirazol-5-olato sodico sustituidoInfo
- Publication number
- PE20140391A1 PE20140391A1 PE2013000943A PE2013000943A PE20140391A1 PE 20140391 A1 PE20140391 A1 PE 20140391A1 PE 2013000943 A PE2013000943 A PE 2013000943A PE 2013000943 A PE2013000943 A PE 2013000943A PE 20140391 A1 PE20140391 A1 PE 20140391A1
- Authority
- PE
- Peru
- Prior art keywords
- pirazole
- compound
- sodium
- substitute
- morfolin
- Prior art date
Links
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 2
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000002425 cardiocirculatory effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
REFERIDA AL COMPUESTO 1- 6- MORFOLIN-4-IL PIRIMIDIN-4-IL -4- 1H-1,2,3-TRIAZOL-1-IL -1H-PIRAZOL-5-OLATO SODICO DE FORMULA (II) EN SU FORMA CRISTALINA. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION QUE CONSISTE EN HACER REACCIONAR EL COMPUESTO 1-[6-(MORFOLIN-4-IL)PIRIMIDIN-4-IL]-4-(1H-1,2,3-TRIAZOL-1-IL)-1H-PIRAZOL-5-OL EN UN DISOLVENTE CON HIDROXIDO DE SODIO O SODA CAUSTICA ACUOSA O UNA SAL SODICA, CON LA ADICION DE UNA BASE TAL COMO TRIETILAMINA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES CARDIO-CIRCULATORIAS, ANEMIA, ENFERMEDADES RENALES CRONICAS E INSUFECIENCIA RENAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044131A DE102010044131A1 (de) | 2010-11-18 | 2010-11-18 | Substituiertes Natrium-1H-pyrazol-5-olat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140391A1 true PE20140391A1 (es) | 2014-03-29 |
Family
ID=44999768
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002012A PE20180324A1 (es) | 2010-11-18 | 2011-11-15 | 1h-pirazol-5-olato sodico sustituido |
| PE2013000943A PE20140391A1 (es) | 2010-11-18 | 2011-11-15 | 1h-pirazol-5-olato sodico sustituido |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002012A PE20180324A1 (es) | 2010-11-18 | 2011-11-15 | 1h-pirazol-5-olato sodico sustituido |
Country Status (46)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102010044131A1 (de) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
| KR102086389B1 (ko) * | 2012-05-08 | 2020-03-09 | 바이엘 파마 악티엔게젤샤프트 | 트리아졸 화합물의 제조 방법 |
| SI3057580T1 (sl) * | 2013-10-17 | 2021-07-30 | Bayer Pharma Aktiengesellschaft | Farmacevtske dozirne oblike, ki vsebujejo natrijev 1-(6-(morfolin-4-il)pirimidin-4-il)-4-(1H-1,2,3-triazol-1-il)-1H- pirazol-5-olat |
| WO2016049537A1 (en) | 2014-09-26 | 2016-03-31 | The Cleveland Clinic Foundation | Treating and preventing disease with tma and tmao lowering agents |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| WO2018149929A1 (en) * | 2017-02-16 | 2018-08-23 | Bayer Pharma Aktiengesellschaft | Combination of reporter gene assays and transcriptional analysis |
| EP3888684A1 (en) * | 2020-03-31 | 2021-10-06 | Bayer Animal Health GmbH | Composition having improved voluntary acceptance |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1519069A (fr) | 1966-04-13 | 1968-03-29 | Geigy Ag J R | Dérivés du sulfanilamide et leur préparation |
| GR63123B (en) | 1975-12-11 | 1979-09-11 | Lilly Co Eli | Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones |
| US4075003A (en) | 1975-12-11 | 1978-02-21 | Eli Lilly And Company | Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones |
| PL103509B1 (pl) | 1976-09-20 | 1979-06-30 | Lilly Co Eli | Srodek chwastobojczy |
| US4663327A (en) | 1984-05-23 | 1987-05-05 | Bayer Aktiengesellschaft | 1-heteroaryl-4-aryl-pyrazolin-5-ones |
| DE3443308A1 (de) | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
| DE3527157A1 (de) | 1985-07-30 | 1987-02-12 | Bayer Ag | 1-heteroaryl-4-aryl-pyrazol-derivate |
| DE4204919A1 (de) | 1992-02-19 | 1993-08-26 | Bayer Ag | Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen |
| JPH0735361B2 (ja) * | 1993-09-09 | 1995-04-19 | 日産化学工業株式会社 | ヒドラゾン誘導体およびその製造方法 |
| FR2725988B1 (fr) | 1994-10-24 | 1997-01-24 | Roussel Uclaf | Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| JPH10306077A (ja) | 1997-05-07 | 1998-11-17 | Daiichi Rajio Isotope Kenkyusho:Kk | ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬 |
| DE19909237A1 (de) | 1999-03-03 | 2000-09-07 | Merck Patent Gmbh | Pyrazol-3-on-derivate |
| US6878729B2 (en) | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| EP2330187B1 (en) | 2001-05-15 | 2016-07-27 | Janssen Pharmaceuticals, Inc. | CD8+ T cells specific for peptide WVDNKTFSV that are specifically cytotoxic for IgE-positive target cells and methods of production. |
| WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| HUP0401567A3 (en) | 2001-09-21 | 2005-06-28 | Solvay Pharm Bv | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them |
| US7569592B2 (en) | 2001-12-18 | 2009-08-04 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| UY27813A1 (es) * | 2002-05-31 | 2003-12-31 | Smithkline Beecham Corp | Inhibidores de la peptido-desformilasa |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7652033B2 (en) | 2003-03-27 | 2010-01-26 | Emory University | HIF-1 inhibitors |
| JP2006522164A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のジアリール置換ピラゾール修飾因子 |
| JP2007527854A (ja) | 2003-05-01 | 2007-10-04 | パナシア ファーマシューティカルズ インコーポレーテッド | 虚血関連状態の治療方法 |
| US7226941B2 (en) | 2003-06-30 | 2007-06-05 | Hif Bio, Inc. | Compound for treating angiogenesis |
| CN1842332A (zh) * | 2003-06-30 | 2006-10-04 | Hif生物公司 | 化合物、组合物及方法 |
| EP1768687A2 (en) | 2004-06-29 | 2007-04-04 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
| DE102008020113A1 (de) | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| CA2601098C (en) | 2005-03-16 | 2011-07-05 | Aventis Pharmaceuticals Inc. | Dipyrazoles as central nervous system agents |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2007121687A1 (en) | 2006-04-26 | 2007-11-01 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament |
| DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| DE102010044131A1 (de) | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
-
2010
- 2010-11-18 DE DE102010044131A patent/DE102010044131A1/de not_active Withdrawn
-
2011
- 2011-11-08 US US13/291,271 patent/US8653074B2/en active Active
- 2011-11-15 MX MX2013004797A patent/MX347670B/es active IP Right Grant
- 2011-11-15 LT LTEP11784992.7T patent/LT2640718T/lt unknown
- 2011-11-15 PL PL11784992T patent/PL2640718T3/pl unknown
- 2011-11-15 SI SI201131516T patent/SI2640718T1/en unknown
- 2011-11-15 MA MA35911A patent/MA34671B1/fr unknown
- 2011-11-15 PT PT117849927T patent/PT2640718T/pt unknown
- 2011-11-15 WO PCT/EP2011/070099 patent/WO2012065967A1/de not_active Ceased
- 2011-11-15 US US13/988,141 patent/US9533972B2/en active Active
- 2011-11-15 CA CA2818002A patent/CA2818002C/en active Active
- 2011-11-15 AP AP2013006922A patent/AP3429A/xx active
- 2011-11-15 EA EA201390703A patent/EA023103B1/ru not_active IP Right Cessation
- 2011-11-15 UA UAA201307718A patent/UA112422C2/uk unknown
- 2011-11-15 PE PE2017002012A patent/PE20180324A1/es unknown
- 2011-11-15 TR TR2018/06652T patent/TR201806652T4/tr unknown
- 2011-11-15 JP JP2013539223A patent/JP5918779B2/ja active Active
- 2011-11-15 AU AU2011331305A patent/AU2011331305B2/en active Active
- 2011-11-15 NZ NZ610614A patent/NZ610614A/en unknown
- 2011-11-15 HU HUE11784992A patent/HUE038024T2/hu unknown
- 2011-11-15 SG SG2013030887A patent/SG189975A1/en unknown
- 2011-11-15 HR HRP20180993TT patent/HRP20180993T1/hr unknown
- 2011-11-15 MY MYPI2013700801A patent/MY167219A/en unknown
- 2011-11-15 AR ARP110104269A patent/AR083887A1/es not_active Application Discontinuation
- 2011-11-15 KR KR1020137012680A patent/KR101984317B1/ko active Active
- 2011-11-15 PH PH1/2013/500997A patent/PH12013500997A1/en unknown
- 2011-11-15 ES ES11784992.7T patent/ES2675580T3/es active Active
- 2011-11-15 EP EP11784992.7A patent/EP2640718B8/de active Active
- 2011-11-15 PE PE2013000943A patent/PE20140391A1/es active IP Right Grant
- 2011-11-15 RS RS20180749A patent/RS57599B1/sr unknown
- 2011-11-15 BR BR112013012223-4A patent/BR112013012223B1/pt active IP Right Grant
- 2011-11-15 CN CN201180055239.3A patent/CN103270031B/zh active Active
- 2011-11-15 DK DK11784992.7T patent/DK2640718T3/da active
- 2011-11-15 CN CN201510059285.0A patent/CN104650047A/zh active Pending
- 2011-11-15 KR KR1020187005194A patent/KR20180023043A/ko not_active Ceased
- 2011-11-16 UY UY0001033736A patent/UY33736A/es active IP Right Grant
- 2011-11-17 JO JOP/2011/0347A patent/JOP20110347B1/ar active
- 2011-11-17 TW TW100141958A patent/TWI516485B/zh active
-
2013
- 2013-04-30 CO CO13109274A patent/CO6741155A2/es not_active Application Discontinuation
- 2013-05-02 CR CR20130196A patent/CR20130196A/es unknown
- 2013-05-03 DO DO2013000096A patent/DOP2013000096A/es unknown
- 2013-05-07 IL IL226192A patent/IL226192A/en active IP Right Grant
- 2013-05-15 GT GT201300125A patent/GT201300125A/es unknown
- 2013-05-16 CL CL2013001390A patent/CL2013001390A1/es unknown
- 2013-05-16 EC ECSP13012627 patent/ECSP13012627A/es unknown
- 2013-05-16 CU CU2013000072A patent/CU20130072A7/es unknown
- 2013-05-17 TN TNP2013000215A patent/TN2013000215A1/fr unknown
- 2013-06-14 ZA ZA2013/04430A patent/ZA201304430B/en unknown
-
2015
- 2015-11-23 HK HK15111529.0A patent/HK1210776A1/xx unknown
-
2018
- 2018-06-28 CY CY20181100675T patent/CY1120375T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140391A1 (es) | 1h-pirazol-5-olato sodico sustituido | |
| BR112013020270A2 (pt) | derivados de pirazol microbicidas | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| CY1118478T1 (el) | Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου | |
| MX2015009389A (es) | Composicion para el tratamiento de material de resina con ataque quimico. | |
| DOP2011000329A (es) | Preparacion de solido | |
| MX344473B (es) | Composicion farmaceutica acuosa semisolida que contiene tapentadol. | |
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| DOP2011000245A (es) | Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica | |
| BR112013017442A2 (pt) | uso de compostos, composição para limpeza ou lavagem, composto, e, processo para preparar compostos | |
| CO7141429A2 (es) | Nuevos compuestos de pirazol | |
| AR114134A2 (es) | Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno | |
| AR114133A2 (es) | Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno | |
| ECSP11010856A (es) | Composición farmacéutica sólida | |
| UY32496A (es) | Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-aril-metil]-heterobenzamida, su preparación y su aplicación en terapéutica. | |
| BR112012008952A2 (pt) | microbicidas | |
| EP2319514A4 (en) | STABLE AQUEOUS SOLUTION COMPOSITION COMPRISING A SULFONAMIDE COMPOUND | |
| BR112012012987A2 (pt) | derivados de diona espiroheterocíclica utilizados como pesticidas. | |
| BR112013024314A2 (pt) | derivados quinolina como fungicidas | |
| WO2007129184A3 (en) | An improved process for the preparation of phenytoin sodium | |
| WO2016026014A8 (pt) | Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer | |
| AR119050A2 (es) | Compuestos del ácido 3,6-diclorosalicílico y procesos de síntesis relacionados | |
| AR109745A2 (es) | Derivado de 4-pirimidinsulfamida | |
| TR200602072A3 (tr) | 3.5 mol kristal sulu çinko borat üretimi. | |
| UY29858A1 (es) | Derivados de la 1-amino-ftalazina sustituida, su preparación y su aplicación en terapéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration |